Press Releases

Year None20222021202020192018

May 11, 2022

Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

April 25, 2022

Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment

April 18, 2022

Black Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study of BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Glioblastoma and Non-Small Cell Lung Cancer

April 07, 2022

Black Diamond Therapeutics to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference

April 07, 2022

Black Diamond Therapeutics Appoints Wendy L. Dixon to its Board of Directors

March 17, 2022

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

March 02, 2022

Black Diamond Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference

February 22, 2022

Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People Officer

January 11, 2022

Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, A MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung Cancer

January 10, 2022

Black Diamond Therapeutics Announces Strategic Priorities and Expected Milestones for 2022

Displaying 11 - 20 of 21